From Bench to Commercial Manufacturing in a Flash
We provide API development and commercial manufacturing solutions. Our proprietary, patented API pharma platform features the STT® continuous flow reactors. Our platform enables rapid synthetic route development and highly automated, controlled and inexpensive deployment of scaled cGMP commercial manufacturing. We have worked closely with the FDA, EPA and industry leaders in AI and ML technologies to ensure that our facilities have the highest regulatory compliance, lowest environmental impact and smallest manufacturing foot print on the planet. These features allow us to drive down drug costs and create a distributive, domestic network of modular manufacturing facilities enabling Medicines-for-Demand.
Our proprietary Magellan 1.2 ml bench-top flow reactor we are able to induce chemical reactions previously thought to be impossible via traditional methods of synthetic route development. As a result of our Ai/ML enabled Magellan 1.2 ml flow reactors we can rapidly develop cost-effective routes with fewer unit reactions and higher yields.
Our state-of-the-art technologies enable new, low-cost, synthetic chemical route development which immediately scales from the bench to cGMP manufacturing without the traditional re-engineering, mass balance and optimization needed to scale a bench chemistry.
We provide the highest level of analytical support to achieve your desired purity and product attribute goals.
WHAT OUR CUSTOMERS THINK
The combination of Bright Path’s patented manufacturing platform and deep chemistry knowledge allowed them to rapidly develop one of our complex molecules where other CDMO providers simply could not deliver. Bright Path Laboratories saved us time and costs.
CEO, RLS Therapeutics
ChemWerth has partnered with Bright Path Laboratories to facilitate their innovative API discovery, development and manufacturing processes because we believe BPL’s solution will result in better, quicker and higher quality solutions to supply global medicine demand.
Chairman and CEO ChemWerth and Werth Family Investment Associates